Journal
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 5, Issue -, Pages -Publisher
AME PUBL CO
DOI: 10.21037/tgh.2019.09.09
Keywords
Liver transplant; peri-transplant management; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); cirrhosis
Categories
Ask authors/readers for more resources
The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly growing, affecting 25% of the world population. Non-alcoholic steatohepatitis (NASH) is the most severe form of NAFLD and affects 1.5% to 6.5% of the world population. Its rising incidence will make end-stage liver disease (ESLD) due to NASH the number one indication for liver transplantation (LT) in the next 10 to 20 years, overtaking Hepatitis C. Patients with NASH also have a high prevalence of associated comorbidities such as type 2 diabetes, obesity, metabolic syndrome, cardiovascular disease, and chronic kidney disease (CKD), which must be adequately managed during the peritransplant period for optimal post-transplant outcomes. The focus of this review article is to provide a comprehensive overview of the unique challenges these patients present in the peritransplant period, which comprises the pre-transplant, intraoperative, and immediate postoperative periods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available